参考文献/References:
[1] Peppard PE,Young T,Barnet JH,et al. Increased prevalence of sleep-disordered breathing in adults[J]. Am J Epidemiol,2013,177(9):1006-1014.
[2] Lim DC,Pack AI. Obstructive sleep apnea:update and future[J]. Annu Rev Med,2017,68:99-112.
[3] Schutz SG,Dunn A,Braley TJ,et al. New frontiers in pharmacologic obstructive sleep apnea treatment:a narrative review[J]. Sleep Med Rev,2021,57:101473.
[4] Dempsey JA,Veasey SC,Morgan BJ,et al. Pathophysiology of sleep apnea[J]. Physiol Rev,2010,90(1):47-112.
[5] Subramani Y,Singh M,Wong J,et al. Understanding phenotypes of obstructive sleep apnea:applications in anesthesia,surgery,and perioperative medicine[J]. Anesth Analg,2017,124(1):179-191.
[6] Pépin JL,Bailly S,Rinder P,et al. CPAP therapy termination rates by OSA phenotype:a French nationwide database analysis[J]. J Clin Med,2021,10(5):936.
[7] Randerath W,de Lange J,Hedner J,et al. Current and novel treatment options for obstructive sleep apnoea[J]. ERJ Open Res,2022,8(2):00126-2022.
[8] Neelapu BC,Kharbanda OP,Sardana HK,et al. Craniofacial and upper airway morphology in adult obstructive sleep apnea patients:a systematic review and meta-analysis of cephalometric studies[J]. Sleep Med Rev,2017,31:79-90.
[9] Gottlieb DJ,Punjabi NM. Diagnosis and management of obstructive sleep apnea:a review[J]. Jama,2020,323(14):1389-1400.
[10] Brown DL,Yadollahi A,He K,et al. Overnight rostral fluid shifts exacerbate obstructive sleep apnea after stroke[J]. Stroke,2021,52(10):3176-3183.
[11] Wang Y,Li CX,Lin YN,et al. The role of aldosterone in OSA and OSA-related hypertension[J]. Front Endocrinol (Lausanne),2021,12:801689.
[12] Eskandari D,Zou D,Grote L,et al. Acetazolamide reduces blood pressure and sleep-disordered breathing in patients with hypertension and obstructive sleep apnea:a randomized controlled trial[J]. J Clin Sleep Med,2018,14(3):309-317.
[13] Kasai T,Bradley TD,Friedman O,et al. Effect of intensified diuretic therapy on overnight rostral fluid shift and obstructive sleep apnoea in patients with uncontrolled hypertension[J]. J Hypertens,2014,32(3):673-680.
[14] Neeland IJ,Eliasson B,Kasai T,et al. The impact of empagliflozin on obstructive sleep apnea and cardiovascular and renal outcomes:an exploratory analysis of the EMPA-REG OUTCOME trial[J]. Diabetes Care,2020,43(12):3007-3015.
[15] Monda VM,Porcellati F,Strollo F,et al. Possible preventative/rehabilitative role of gliflozins in OSA and T2DM. a systematic literature review-based hypothesis[J]. Adv Ther,2021,38(8):4195-4214.
[16] Blackman A,Foster GD,Zammit G,et al. Effect of liraglutide 3.0mg in individuals with obesity and moderate or severe obstructive sleep apnea:the SCALE sleep apnea randomized clinical trial[J]. Int J Obes (Lond),2016,40(8):1310-1319.
[17] Braley TJ,Huber AK,Segal BM,et al. A randomized,subject and rater-blinded,placebo-controlled trial of dimethyl fumarate for obstructive sleep apnea[J]. Sleep,2018,41(8):10.1093.
[18] Carley DW,Olopade C,Ruigt GS,et al. Efficacy of mirtazapine in obstructive sleep apnea syndrome[J]. Sleep,2007,30(1):35-41.
[19] Prasad B,Radulovacki MG,Carley DW. Proof of concept trial of dronabinol in obstructive sleep apnea[J]. Front Psychiatry,2013,4:1.
[20] Carley DW,Prasad B,Reid KJ,et al. Pharmacotherapy of apnea by cannabimimetic enhancement,the PACE clinical trial:effects of dronabinol in obstructive sleep apnea[J]. Sleep,2018,41(1):zsx184.
[21] Taranto-Montemurro L,Messineo L,Sands SA,et al. The combination of atomoxetine and oxybutynin greatly reduces obstructive sleep apnea severity. a randomized,placebo-controlled,double-blind crossover trial[J]. Am J Respir Crit Care Med,2019,199(10):1267-1276.
[22] Bart Sangal R,Sangal JM,Thorp K. Atomoxetine improves sleepiness and global severity of illness but not the respiratory disturbance index in mild to moderate obstructive sleep apnea with sleepiness[J]. Sleep Med,2008,9(5):506-510.
[23] Schmickl CN,Edwards BA,Malhotra A. Drug therapy for obstructive sleep apnea:are we there yet?[J]. Am J Respir Crit Care Med,2022,205(12):1379-1381.
[24] Ferrannini E. Sodium-glucose co-transporters and their inhibition:clinical physiology[J]. Cell Metab,2017,26(1):27-38.
[25] Tanriover C,Ucku D,Akyol M,et al. Potential use of SGLT-2 inhibitors in obstructive sleep apnea:a new treatment on the horizon[J]. Sleep Breath,2023,27(1):77-89.
[26] Tang Y,Sun Q,Bai XY,et al. Effect of dapagliflozin on obstructive sleep apnea in patients with type 2 diabetes:a preliminary study[J]. Nutr Diabetes,2019,9(1):32.
[27] Wan N,Rahman A,Hitomi H,et al. The effects of sodium-glucose cotransporter 2 inhibitors on sympathetic nervous activity[J]. Front Endocrinol (Lausanne),2018,9:421.
[28] Schütz SG,Dunn A,Braley TJ,et al. New frontiers in pharmacologic obstructive sleep apnea treatment:A?narrative review[J]. Sleep Med Rev,2021,57:101473.
[29] Sato T,Aizawa Y,Yuasa S,et al. The effect of dapagliflozin treatment on epicardial adipose tissue volume[J]. Cardiovasc Diabetol,2018,17(1):6.
[30] Hollander P,Hill J,Johnson J,et al. Results of VERTIS SU extension study:safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin[J]. Curr Med Res Opin,2019,35(8):1335-1343.
[31] Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1[J]. Cell Metab,2018,27(4):740-756.
[32] Wu Y,Zhang A,Hamilton DJ,et al. Epicardial fat in the maintenance of cardiovascular health[J]. Methodist Debakey Cardiovasc J,2017,13(1):20-24.
[33] Puig F,Rico F,Almendros I,et al. Vibration enhances interleukin-8 release in a cell model of snoring-induced airway inflammation[J]. Sleep,2005,28(10):1312-1316.
[34] Kim M,Cho SW,Won TB,et al. Associations between systemic inflammatory markers based on blood cells and polysomnographic factors in obstructive sleep apnea[J]. Clin Exp Otorhinolaryngol,2023,16(2):159-164.
[35] Schmickl CN,Li Y,Orr JE,et al. Effect of venlafaxine on apnea-hypopnea index in patients with sleep apnea:a randomized,double-blind crossover study[J]. Chest,2020,158(2):765-775.
[36] Marshall NS,Yee BJ,Desai AV,et al. Two randomized placebo-controlled trials to evaluate the efficacy and tolerability of mirtazapine for the treatment of obstructive sleep apnea[J]. Sleep,2008,31(6):824-831.
[37] Calik MW,Radulovacki M,and Carley DW. Intranodose ganglion injections of dronabinol attenuate serotonin-induced apnea in Sprague-Dawley rat[J]. Respir Physiol Neurobiol,2014,190:20-24.
[38] Taranto-Montemurro L,Sands SA,Edwards BA,et al. Desipramine improves upper airway collapsibility and reduces OSA severity in patients with minimal muscle compensation[J]. Eur Respir J,2016,48(5):1340-1350.
[39] Arens P,Fischer T,Dommerich S,et al. Ultrasound shear wave elastography of the tongue during selective hypoglossal nerve stimulation in patients with obstructive sleep apnea syndrome[J]. Ultrasound Med Biol,2021,47(10):2869-2879.
[40] Niakani S,Liu H,Liu WY,et al. Differential pharmacological and sex-specific effects of antimuscarinic agents at the hypoglossal motor nucleus in vivo in rats[J]. Sci Rep,2022,12(1):14896.
[41] Lim R,Messineo L,Grunstein RR,et al. The noradrenergic agent reboxetine plus the antimuscarinic hyoscine butylbromide reduces sleep apnoea severity:a double-blind,placebo-controlled,randomised crossover trial[J]. J Physiol,2021,599(17):4183-4195.
[42] Wang D,Marshall NS,Duffin J,et al. Phenotyping interindividual variability in obstructive sleep apnoea response to temazepam using ventilatory chemoreflexes during wakefulness[J]. J Sleep Res,2011,20(4):526-532.
[43] Dinges DF,Weaver TE. Effects of modafinil on sustained attention performance and quality of life in OSA patients with residual sleepiness while being treated with nCPAP[J]. Sleep Med,2003,4(5):393-402.
[44] Avellar AB,Carvalho LB,Prado GF,et al. Pharmacotherapy for residual excessive sleepiness and cognition in CPAP-treated patients with obstructive sleep apnea syndrome:a?systematic review and meta-analysis[J]. Sleep Med Rev,2016,30:97-107.
相似文献/References:
[1]黄淮滨 刘甲兴.肥厚型心肌病治疗新靶点——钙脱敏治疗[J].心血管病学进展,2019,(7):1047.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.021]
HUANG HuaibinLIU Jiaxing.A Novel Target for Therapy in Hypertrophic Cardiomyopathy: Ca2+ desensitizer[J].Advances in Cardiovascular Diseases,2019,(8):1047.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.021]
[2]凌梦军 陈明凌梦军.阻塞性睡眠呼吸暂停低通气综合征与高血压关系的研究进展[J].心血管病学进展,2019,(5):722.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.015]
[3]李可 田进文 邓珏琳.老年高血压的临床诊治研究进展[J].心血管病学进展,2019,(9):1208.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.006]
LI Ke,TIAN Jinwen,DENG Juelin.Diagnosis and Treatment in Elderly Hypertension[J].Advances in Cardiovascular Diseases,2019,(8):1208.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.006]
[4]罗芩 何庆.TNF凝集素样结构域：高原肺水肿药物治疗新选择罗芩 何庆2[J].心血管病学进展,2019,(9):1301.[doi:10.16806/j.cnki.issn.1004-3934.2019.00.030]
LUO QinHE Qing.The Lectin-like Domain of TNF:New Drug Treatment Option for HAPE[J].Advances in Cardiovascular Diseases,2019,(8):1301.[doi:10.16806/j.cnki.issn.1004-3934.2019.00.030]
[5]郭岐龙 芦颜美 张玲 张疆华 邢强 祖克拉·吐尔洪 李耀东 周贤惠 汤宝鹏.新疆地区老年慢性心力衰竭住院患者的病因、合并症及药物治疗的多中心回顾性分析[J].心血管病学进展,2020,(4):414.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.021]
GUO Qilong,LU Yanmei,ZHANG Ling,et al.Etiology, Comorbidity and Drug Treatment of Elderly Inpatients with Chronic Heart Failure in Xinjiang: A Multi-center Retrospective Study[J].Advances in Cardiovascular Diseases,2020,(8):414.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.021]
[6]布热比古力·阿布力米提 付真彦.乳腺癌药物治疗与心肌损伤[J].心血管病学进展,2020,(8):802.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.005]
Burebiguli·abulimitiFU Zhenyan.Drug Therapy of Breast Cancer and Assosiated Myocardial Damage[J].Advances in Cardiovascular Diseases,2020,(8):802.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.005]
[7]杨鹏辉 李谧.巨大动脉导管未闭治疗研究进展[J].心血管病学进展,2021,(1):68.[doi:10.16806/j.cnki.issn.1004-3934.20.01.000]
YANG Penghui,LI Mi.Treatment of Large Patent Ductus Arteriosus[J].Advances in Cardiovascular Diseases,2021,(8):68.[doi:10.16806/j.cnki.issn.1004-3934.20.01.000]
[8]文芳 王宏宇.阻塞性睡眠呼吸暂停与心血管相关疾病的关系研究进展[J].心血管病学进展,2021,(4):302.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.004]
WEN Fang,WANG Hongyu.Relationship between Obstructive Sleep Apnea and Cardiovascular Related Diseases[J].Advances in Cardiovascular Diseases,2021,(8):302.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.004]
[9]王毅 佘强.射血分数降低性心力衰竭的药物进展[J].心血管病学进展,2021,(11):990.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
WANG Yi,SHE Qiang.Advancement of Drug Therapy in Heart Failure with Reduced Ejection Fraction[J].Advances in Cardiovascular Diseases,2021,(8):990.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
[10]于筱斋?高艳香?郭紫玉?陈西霞?叶子翔?郑金刚.非阻塞性冠状动脉疾病的冠状动脉微循环功能障碍治疗新进展[J].心血管病学进展,2022,(5):385.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.001]
YU Xiaozhai,GAO Yanxiang,GUO Ziyu,et al.Treatment of Coronary Microvascular Dysfunction in Non-Obstructive Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2022,(8):385.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.001]